Ohio’s AtriCure (NSDQ:ATRC) is promoting 1 of its cryoablation devices for a new indication, temporary pain relief for some cardiac surgery patients.
AtriCure said its CryoIce ablation probe is designd to temporarily manage pain through cryoanalgesia, or ablating the affected nerves. The technique can pause the transmission of pain impulses to the brain for days or even weeks, the company said.
The CryoIce device’s expanded indication is for the ablation of intercostal nerve bundles to block thoracotomy incision-related pain in cardiac and thoracic surgery patients. The device is already cleared to treat cardiac arrhythmias and to block pain through temporarily ablation of peripheral nerves.
"Broadening the CryoIce indication displays AtriCure’s commitment to collaborating with surgeons on new solutions to deliver improved patient care," president & CEO Mike Carrel said in prepared remarks.
Last November AtriCure won an FDA investigational device exemption for a 1st-of-its-find clinical trial designed to test two kinds of ablation for patients with non-aroxysmal atrial fibrillation.
